Recently, the China Drug Administration approved the marketing of Opreton tablets, a Class 1 innovative drug declared by Takeda Pharmaceuticals U.S.A., Inc. for use in adolescents aged 16 and above and adults with type 1 narcolepsy. In addition, recently, the State Drug Administration approved the marketing of the Class 1 innovative drug siprocopan succinate tablets declared by Sichuan Hisco Pharmaceutical Co., Ltd. through a priority review and approval procedure. It is suitable for treating adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors.

Recently, the China Drug Administration approved the marketing of Opreton tablets, a Class 1 innovative drug declared by Takeda Pharmaceuticals U.S.A., Inc. for use in adolescents aged 16 and above and adults with type 1 narcolepsy. In addition, recently, the State Drug Administration approved the marketing of the Class 1 innovative drug siprocopan succinate tablets declared by Sichuan Hisco Pharmaceutical Co., Ltd. through a priority review and approval procedure. It is suitable for treating adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors.